Ulcerative colitis (UC) is a multifactorial intestinal disease with a high incidence. In recent years, there has been an urgent need for pleiotropic drugs with a clear biosafety profile. Tacrolimus (TAC) is an immunosuppressant with stronger in vivo effects and better gastrointestinal absorption and is considered a potential treatment for UC. FKBP12 is a mediator of TAC immunosuppression; however, it is unclear whether it can participate in the development of UC in combination with TAC. The purpose of this study is to preliminarily validate the function of FKBP12 by establishing dextran sulfate sodium (DSS)-induced UC model and TAC treatment. The results revealed that TAC was effective in alleviating DSS-induced UC symptoms such as body weight and disease activity index (DAI). TAC significantly protects colonic tissue and attenuates DSS-induced histomorphological changes. In addition, FKBP12 is down-regulated in the intestinal tissue of DSS-induced UC mice and in serum samples of UC patients. In conclusion, our study revealed that FKBP12 may act as a TAC receptor to have anti-inflammatory and protective effects on DSS-induced UC in mice, which will provide a new option for the treatment of UC.
Keyphrases
- high glucose
- diabetic rats
- ulcerative colitis
- disease activity
- rheumatoid arthritis
- oxidative stress
- type diabetes
- systemic lupus erythematosus
- endothelial cells
- body weight
- anti inflammatory
- risk factors
- risk assessment
- metabolic syndrome
- physical activity
- newly diagnosed
- rheumatoid arthritis patients
- chronic kidney disease
- adipose tissue
- prognostic factors
- skeletal muscle
- climate change
- insulin resistance
- replacement therapy
- sleep quality
- patient reported